Song Wenrong1,
Zhang Lei2,
Pan Zaoxia3,
Ding Mingyan4,
Luo Baochang5,
Li Qiong6 
For correspondence:- Li Qiong Email: el1181@163.com
Accepted: 23 December 2018 Published: 31 January 2019
Citation: Wenrong S, Lei Z, Zaoxia P, Mingyan D, Baochang L, Qiong L. Effects of sitagliptin on blood glucose, lipids, pancreatic ^6; cell secretory function and insulin resistance in patients with type 2 diabetes mellitus. Trop J Pharm Res 2019; 18(1):151-155 doi: 10.4314/tjpr.v18i1.23
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To study the influence of sitagliptin on blood glucose, lipid and pancreatic β cell function in type II diabetes mellitus (T2DM) patients.
Methods: Two groups of T2DM patients (100/group) received either metformin only (control group), or metformin plus sitaglipin (study group) for 3 months. Blood lipid profiles, fasting blood glucose (FBG), indices of pancreatic function and insulin resistance were assayed using standard biochemical methods.
Results: The metformin-sitaglipin combination resulted in significant decreases in FBG, 2-h PBG, HbAlc total cholesterol (TC), triacylglycerol, and low-density lipoprotein cholesterol (LDL-C), when compared with the metformin-only treatment (p < 0.05). Although there were significant decreases in pancreatic secretion of insulin, fasting insulin, and 2 h postprandial insulin in the two groups, these parameters were significantly lower in the metformin-only treated patients than in those with combination treatment (p < 0.05).
Conclusion: Sitagliptin normalizes fasting blood glucose, lipid profiles and insulin secretion in type II diabetes mellitus (T2DM) patients.
Fulltext in PDF